- Recruiting
NCT04855929: Phase 1: Safety and Therapeutic Activity of ANV419 in RRMM - ANV419-001
NCT04855929: Phase 1: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma. (ANV419-001)
NCT04855929: Phase 1: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma. (ANV419-001)
Sponsor
ClinicalTrials.gov Identifier: NCT04855929
Official Title: ANV419 Single Agent First in Human Study Phase 1: Open-label, Dose Escalation Study in Patients With Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma
First Posted: April 22, 2021
Click here for details on Clinicaltrials.gov
CD122-selective IL-2/Anti-CD25 Antibody-like Fusion Protein ANV419 (Code C180674)
Antibody-like Fusion Protein ANV419
ANV 419
ANV-419
ANV419
CD122-selective IL-2/Anti-CD25 Antibody-like Fusion Protein ANV419
CD122-selective IL-2/Anti-IL-2Ra Antibody Fusion Protein ANV419
Drug: ANV419
Locations
Europe
Spain
Switzerland
United Kingdom